- Mucosal Schwann Cell Hamartoma in Colorectal Mucosa: A Rare Benign Lesion That Resembles Gastrointestinal Neuroma
-
Jiheun Han, Yosep Chong, Tae-Jung Kim, Eun Jung Lee, Chang Suk Kang
-
J Pathol Transl Med. 2017;51(2):187-189. Published online August 25, 2016
-
DOI: https://doi.org/10.4132/jptm.2016.07.02
-
-
9,057
View
-
186
Download
-
10
Citations
-
PDF
-
Citations
Citations to this article as recorded by 
- Multiple non-polypoid mucosal Schwann cell hamartomas presenting as edematous and submucosal tumor-like lesions: a case report
Takeshi Okamoto, Takaaki Yoshimoto, Katsuyuki Fukuda BMC Gastroenterology.2021;[Epub] CrossRef - Mucosal schwann cell hamartoma of the gall bladder
Kanika Sharma, AnjanKumar Dhua, Prabudh Goel, Vishesh Jain, DevendraKumar Yadav, Prashant Ramteke Journal of Indian Association of Pediatric Surgeons.2021; 26(3): 182. CrossRef - Mucosal Schwann Cell Hamartoma in sigmoid colon – A rare case report and review of literature
Xiuyan Feng, Hongzhi Xu, Nestor Dela Cruz Human Pathology: Case Reports.2020; 19: 200337. CrossRef - Spindle cell proliferations of the sigmoid colon, rectum and anus: a review with emphasis on perineurioma
Patrice Grech, John B Schofield Histopathology.2020; 76(3): 342. CrossRef - Mucosal Schwann cell hamartoma of the gastroesophageal junction: A series of 6 cases and comparison with colorectal counterpart
Yuan Li, Pouneh Beizai, John W. Russell, Lindsey Westbrook, Arash Nowain, Hanlin L. Wang Annals of Diagnostic Pathology.2020; 47: 151531. CrossRef - Mucosal Schwann Cell Hamartoma Presenting as Diffuse Fine Nodularities
Han Beol Jang, Jong Ok Kim, Sang-Bum Kang The Korean Journal of Gastroenterology.2020; 76(3): 171. CrossRef - A case of Schwann cell hamartoma of the tongue
Saya TAKIKAWA, Shigeo TANAKA, Masamichi KOMIYA, Masaaki SUEMITSU, Tadahiko UTSUNOMIYA, Kayo KUYAMA Japanese Journal of Oral and Maxillofacial Surgery.2020; 66(12): 601. CrossRef - Hamartoma de células de Schwann mucoso: revisión de una entidad descrita recientemente
Francisco García-Molina, José Antonio Ruíz-Macia, Joaquin Sola Revista Española de Patología.2018; 51(1): 49. CrossRef - Neural and neurogenic tumours of the gastroenteropancreaticobiliary tract
Aoife J McCarthy, Dipti M Karamchandani, Runjan Chetty Journal of Clinical Pathology.2018; 71(7): 565. CrossRef - Case of colonic mucosal Schwann cell hamartoma and review of literature on unusual colonic polyps
JayaKrishna Chintanaboina, Kofi Clarke BMJ Case Reports.2018; : bcr-2018-224931. CrossRef
- PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
-
Jiheun Han, Yongkil Hong, Youn Soo Lee
-
J Pathol Transl Med. 2017;51(1):40-48. Published online December 15, 2016
-
DOI: https://doi.org/10.4132/jptm.2016.08.31
-
-
12,816
View
-
264
Download
-
29
Citations
-
Abstract
PDF
- Background
Programmed death ligand 1 (PD-L1) in tumor cells is known to promote immune escape of cancer by interacting with programmed cell death 1 (PD-1) in tumor infiltrating immune cells. Immunotherapy targeting these molecules is emerging as a new strategy for the treatment of glioblastoma (GBM). Understanding the relationship between the PD-L1/PD-1 axis and prognosis in GBM patients may be helpful to predict the effects of immunotherapy.
Methods PD-L1 expression and PD-1–positive tumor infiltrating mononuclear cell (PD-1+tumor infiltrating mononuclear cell [TIMC]) density were evaluated using tissue microarray containing 54 GBM cases by immunohistochemical analysis; the associations with patient clinical outcomes were evaluated.
Results PD-L1 expression and high PD-1+TIMC density were observed in 31.5% and 50% of GBM cases, respectively. High expression of PD-L1 in tumor cells was an independent and significant predictive factor for worse overall survival (OS; hazard ratio, 4.958; p = .007) but was not a significant factor in disease-free survival (DFS). PD-1+TIMC density was not correlated with OS or DFS. When patients were classified based on PD-1 expression and PD-1+TIMC density, patients with PD-L1+/PD-1+TIMC low status had the shortest OS (13 months, p = .009) and DFS (7 months, p = .053).
Conclusions PD-L1 expression in GBM was an independent prognostic factor for poor OS. In addition, combined status of PD-L1 expression and PD-1+TIMC density also predicted patient outcomes, suggesting that the therapeutic role of the PD-1/PD-L1 axis should be considered in the context of GBM immunity.
-
Citations
Citations to this article as recorded by 
- Expression, prognostic significance and therapeutic implications of PD‐L1 in gliomas
Gayaththri Vimalathas, Bjarne Winther Kristensen Neuropathology and Applied Neurobiology.2022;[Epub] CrossRef - PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma
Carolina Noronha, Ana Sofia Ribeiro, Ricardo Taipa, Dina Leitão, Fernando Schmitt, Joaquim Reis, Cláudia Faria, Joana Paredes Journal of Neuro-Oncology.2022; 156(3): 453. CrossRef - Assessment of radiographic and prognostic characteristics of programmed death-ligand 1 expression in high-grade gliomas
Makoto Ohno, Shigehisa Kitano, Kaishi Satomi, Akihiko Yoshida, Yasuji Miyakita, Masamichi Takahashi, Shunsuke Yanagisawa, Yukie Tamura, Koichi Ichimura, Yoshitaka Narita Journal of Neuro-Oncology.2022; 160(2): 463. CrossRef - The prognostic significance of PD-L1 expression in patients with glioblastoma: A meta-analysis
Xin Guo, Yuelin Zhang, Hengxing Jiao, Xingyu Miao Frontiers in Oncology.2022;[Epub] CrossRef - LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway
Xiaoming Wang, Yan Zhang, Jian Zheng, Cuixian Yao, Xiubo Lu Cancer Immunology, Immunotherapy.2021; 70(8): 2235. CrossRef - Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma
Kelsey Maddison, Moira C. Graves, Nikola A. Bowden, Michael Fay, Ricardo E. Vilain, Sam Faulkner, Paul A. Tooney Oncotarget.2021; 12(21): 2177. CrossRef - A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology
Mahdi Abdoli Shadbad, Zahra Asadzadeh, Negar Hosseinkhani, Afshin Derakhshani, Nazila Alizadeh, Oronzo Brunetti, Nicola Silvestris, Behzad Baradaran Frontiers in Immunology.2021;[Epub] CrossRef - Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset
Huan Wang, Youchao Xiao, Xingguang Ren, Dahai Wan Bioengineered.2021; 12(2): 10366. CrossRef - Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma
Nyall R. London, Lisa M. Rooper, Justin A. Bishop, Haiying Xu, Lydia J. Bernhardt, Masaru Ishii, Christine L. Hann, Janis M. Taube, Evgeny Izumchenko, Daria A. Gaykalova, Gary L. Gallia World Neurosurgery.2020; 135: e187. CrossRef - CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas
Joseph A. Flores-Toro, Defang Luo, Adithya Gopinath, Matthew R. Sarkisian, James J. Campbell, Israel F. Charo, Rajinder Singh, Thomas J. Schall, Meenal Datta, Rakesh K. Jain, Duane A. Mitchell, Jeffrey K. Harrison Proceedings of the National Academy of Sciences.2020; 117(2): 1129. CrossRef - Treatment Results for Recurrent Glioblastoma and Alteration of Programmed Death-Ligand 1 Expression After Recurrence
Kyoung Su Sung, Tae Hoon Roh, Ju Hyung Moon, Eui Hyun Kim, Seok-Gu Kang, Se Hoon Kim, Jong Hee Chang World Neurosurgery.2020; 135: e459. CrossRef - Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma
Chang Shu, Qingguo Li Critical Reviews in Oncology/Hematology.2020; 151: 102965. CrossRef - PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis
Chengcheng Hao, Gang Chen, Huishan Zhao, Yan Li, Jianxin Chen, Hongmei Zhang, Shan Li, Yuze Zhao, Feng Chen, Wenbin Li, Wen G. Jiang Frontiers in Oncology.2020;[Epub] CrossRef - Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook
Patrick C. Gedeon, Cosette D. Champion, Kristen E. Rhodin, Karolina Woroniecka, Hanna R. Kemeny, Alexa N. Bramall, Joshua D. Bernstock, Bryan D. Choi, John H. Sampson Expert Review of Clinical Pharmacology.2020; 13(10): 1147. CrossRef - Current clinical management of elderly patients with glioma
Alessia Pellerino, Francesco Bruno, Valeria Internò, Roberta Rudà, Riccardo Soffietti Expert Review of Anticancer Therapy.2020; 20(12): 1037. CrossRef - The Prognostic and Therapeutic Value of PD-L1 in Glioma
Ruo Qiao Chen, Feng Liu, Xin Yao Qiu, Xiao Qian Chen Frontiers in Pharmacology.2019;[Epub] CrossRef - Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Xin Wang, Gaochao Guo, Hui Guan, Yang Yu, Jie Lu, Jinming Yu Journal of Experimental & Clinical Cancer Research.2019;[Epub] CrossRef - Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma
Xiao Shi, Peng-Cheng Yu, Bo-Wen Lei, Cui-Wei Li, Yan Zhang, Li-Cheng Tan, Rong-Liang Shi, Jie Wang, Ben Ma, Wei-Bo Xu, Xiao Wang, Jia-Qian Hu, Nai-Si Huang, Wen-Jun Wei, Yu Wang, Tong-Zhen Chen, Yu-Long Wang, Qing-Hai Ji Thyroid.2019; 29(9): 1269. CrossRef - The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling
Ruo Qiao Chen, Xiao Hong Xu, Feng Liu, Chun Yang Li, Yuan Jun Li, Xiang Rui Li, Guo Yong Jiang, Feng Hu, Di Liu, Feng Pan, Xin Yao Qiu, Xiao Qian Chen Frontiers in Oncology.2019;[Epub] CrossRef - Analysis of PD-L1 expression in salivary duct carcinoma with its efficacy as a tumor marker
Yong Ju Lee, Yoon Woo Koh, Sun Och Yoon, Hyang Joo Ryu, Hye Ryun Kim, Hyang Ae Shin Korean Society for Head and Neck Oncology.2019; 35(1): 13. CrossRef - Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma
Kyu Sang Lee, Kyoungyul Lee, Sumi Yun, Seyoung Moon, Yujun Park, Jung Ho Han, Chae-Yong Kim, Hye Seung Lee, Gheeyoung Choe Journal of Neuro-Oncology.2018; 136(3): 453. CrossRef - Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma
Hyo Jung An, Gyung Hyuck Ko, Jeong-Hee Lee, Jong Sil Lee, Dong Chul Kim, Jung Wook Yang, Min Hye Kim, Jin Pyeong Kim, Eun Jung Jung, Dae Hyun Song Journal of Pathology and Translational Medicine.2018; 52(1): 9. CrossRef - Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?
Michele Porcu, Cinzia Solinas, Paolo Garofalo, Evandro de Azambuja, Mario Scartozzi, Karen Willard-Gallo, Matthias Preusser, Luca Saba Critical Reviews in Oncology/Hematology.2018; 126: 135. CrossRef - The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma
Fumihiko Sato, Jun Akiba, Akihiko Kawahara, Yoshiki Naito, Takeharu Ono, Yorihiko Takase, Kazuya Murata, Hideyuki Abe, Tomohiko Yamaguchi, Hiroaki Miyoshi, Yushi Abe, Yutaro Mihara, Masahiko Tanikawa, Momoko Akashi, Hirofumi Kurose, Hirohito Umeno, Hirohi Journal of Oral Pathology & Medicine.2018; 47(7): 683. CrossRef - Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma
Dwight Owen, Benjamin Chu, Amy M. Lehman, Lakshmanan Annamalai, Jennifer H. Yearley, Konstantin Shilo, Gregory A. Otterson Journal of Thoracic Oncology.2018; 13(8): 1204. CrossRef - PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies
Noah Frydenlund, Meera Mahalingam Human Pathology.2017; 66: 13. CrossRef - Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma
Russell Maxwell, Christopher M. Jackson, Michael Lim Current Treatment Options in Oncology.2017;[Epub] CrossRef - Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy
Joshua Bernstock, Daniel Ye, Florian Gessler, Luca Peruzzotti-Jametti, Mark Gilbert, Yves Pommier, Stefano Pluchino, Ichiro Nakano, John Hallenbeck Matters.2017;[Epub] CrossRef - Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma
Song Xue, Man Hu, Peifeng Li, Ji Ma, Li Xie, Feifei Teng, Yufang Zhu, Bingjie Fan, Dianbin Mu, Jinming Yu Oncotarget.2017; 8(30): 49702. CrossRef
|